Investigational drug · Phase 2
TAK-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Celiac Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "TAK-101"
First trial start
2022
Jun 23, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TAK-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Celiac Disease
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TAK-101" as an intervention, largest first.
- Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free DietPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT04530123 · 102 participants · Start Jun 23, 2022 · Primary completion Dec 9, 2025
Drug: Placebo; TAK-101 · For: Celiac Disease
Sites: Scottsdale, Arizona; Escondido, California; Poway, California · 48 sites in all
- Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac DiseaseCompleted
TakedaTakeda (TAK)
NCT03738475 · 34 participants · Start Nov 11, 2018 · Primary completion Jun 24, 2019
Drug: TIMP-GLIA; Placebo · For: Celiac Disease
Sites: Jacksonville, Florida; Meridian, Idaho; Indianapolis, Indiana · 8 sites in all
- Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac DiseaseCompleted
TakedaTakeda (TAK)
NCT03486990 · 23 participants · Start Jan 23, 2018 · Primary completion May 24, 2019
Drug: TIMP-GLIA · For: Celiac Disease
Sites: Jacksonville, Florida; Boston, Massachusetts; Rochester, Minnesota · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments.
Girbal-González M, Pérez-Cano FJ · Nutrients 2025
- TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study.
Kelly CP, Murray JA, Leffler DA, et al. · Gastroenterology 2021
Also in development for Celiac Disease
- AmlitelimabSAR445229Phase 39 trials
Sanofi · Dermatitis Atopic, Coeliac Disease, Celiac Disease
- TEV-53408Phase 32 trials
Teva · Vitiligo, Celiac Disease
- Larazotide AcetatePhase 31 trial
Interlude Biopharma Co. · Celiac Disease, Celiac Disease in Adolescents
- DONQ52Phase 21 trial
Chugai Pharmaceutical · Celiac Disease
- FB102Phase 21 trial
Forte Biosciences, Inc. · Celiac Disease
- KAN-101Phase 21 trial
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA · Celiac Disease, Coeliac Disease
- ZED1227Phase 21 trial
Dr. Falk Pharma GmbH · Celiac Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.